Today: 29 June 2026
Browse Category

NASDAQ:CMND 13 November 2025 - 18 November 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine Inc. is back in the spotlight today after releasing positive top-line results from the first cohort of its FDA‑approved Phase I/IIa clinical trial for CMND‑100 in alcohol use disorder. The update lands just one day after the company highlighted a new Israeli patent filing for a non‑hallucinogenic depression therapy, and as a fresh equity offering is expected to close around today’s date. GlobeNewswire+2GlobeNewswire+2 The cluster of announcements is drawing intense trading interest. As of mid‑afternoon on November 18, CMND shares were changing hands around $0.27, after touching an intraday high near $0.39, on tens of millions of shares traded – dramatically above the stock’s average daily volume under 1 million shares. Stocktwits
18 November 2025
··
Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Clearmind Medicine (CMND) Stock Soars as FDA‑Regulated Alcohol Use Disorder Trial Expands to Hadassah – November 13, 2025

Vancouver / Jerusalem – November 13, 2025 – Shares of Clearmind Medicine Inc., a clinical‑stage psychedelic and neuroplastogen biotech company, jumped sharply on Thursday after the firm announced final approval to expand its FDA‑regulated Phase 1/2a clinical trial for Alcohol Use Disorder to Hadassah Medical Center in Jerusalem. GlobeNewswire+1 At the same time, Clearmind filed a new Form 6‑K detailing a registered direct offering of shares and pre‑funded warrants, adding fresh capital but also raising dilution questions for investors. Stock Titan
13 November 2025
··

Stock Market Today

  • ASX Penny Stocks: Alligator Energy, Hearts and Minds, Hansen Technologies in Focus
    June 29, 2026, 3:56 PM EDT. Penny stocks on the ASX are grabbing attention as volatility continues. Alligator Energy (ASX:AGE) is still pre-revenue, valued at A$230.73 million, and betting on uranium exploration. The company is running deeper losses but says its cash should last 2.7 years, and analysts see a possible 62.8% jump in shares. Hearts and Minds Investments (ASX:HM1) has a market cap of A$670.92 million. The investment firm's profits are down 84.9%, and its 6.48% dividend yield has investors wondering about longevity. Hansen Technologies sits at a A$904.29 million market cap, pulling in revenue from its Energy & Utilities business. Together, the names show the range of plays and issues in the ASX penny stock scene.
Go toTop